peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

oral non-peptide GLP-1

Orforglipron

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Compared with GLP-1 RAs that bind an orthosteric peptide site, orforglipron is described as binding the receptor’s upper helical bundle. Secondary outcome assessment includes sleep apnea-specific hypoxic burden, PROMIS sleep-related impairment, high-sensitivity C-reactive protein, and body weight.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

Orforglipron is described as a biased partial agonist favoring G-protein signaling, leading to cyclic AMP generation while limiting β-arrestin recruitment and reducing receptor internalization.

Sources[4]pubmedPotential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.It acts as a G-protein-biased partial agonist that stimulates cyclic AMP production, with minimal β-arrestin recruitment and decreased receptor internalization.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “It acts as a G-protein-biased partial agonist that stimulates cyclic AMP production, with minimal β-arrestin recruitment and decreased receptor internalization.”

    Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. · Abstract

    pubmed:42582425:db5c8b1fb3a8:db5c8b1fb3a8

Mechanism

Compared with GLP-1 RAs that bind an orthosteric peptide site, orforglipron is described as binding the receptor’s upper helical bundle.

Sources[4]pubmedPotential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.Unlike its predecessors, which bind an orthosteric peptide site, orforglipron binds the upper helical bundle of the same receptor.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Unlike its predecessors, which bind an orthosteric peptide site, orforglipron binds the upper helical bundle of the same receptor.”

    Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. · Abstract

    pubmed:42582425:db5c8b1fb3a8:db5c8b1fb3a8

Mechanism

In the described Phase 3 trials, the investigational product is administered as an orforglipron capsule formulation and compared with placebo.

Sources[2]pubmedOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.Participants are randomly assigned to placebo or orforglipron capsule formulation
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Participants are randomly assigned to placebo or orforglipron capsule formulation”

    Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. · METHODS

    pubmed:42383207:f6b63476bfbd:f6b63476bfbd

What has been studied?

What the evidence says.

Comparative evidence

An anchored indirect treatment comparison was performed using individual-level data from one study (OASIS 4) and aggregate-level data from another (ATTAIN-1).

Sources[1]pubmedOral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.[1]pubmedOral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.”

    Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. · MATERIALS AND METHODS

    pubmed:42225305:44ec8ec6b2a2:44ec8ec6b2a2
  2. supports · Source-backed record
    “Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).”

    Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. · MATERIALS AND METHODS

    pubmed:42225305:44ec8ec6b2a2:44ec8ec6b2a2

Comparative evidence

The master protocol comprises two Phase 3 studies with multicenter enrollment, randomization, double blinding, and placebo control.

Sources[2]pubmedOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.ATTAIN-OSA is a master protocol with two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “ATTAIN-OSA is a master protocol with two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials”

    Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. · METHODS

    pubmed:42383207:f6b63476bfbd:f6b63476bfbd

Comparative evidence

The evidence synthesis was restricted to randomized trials where oral GLP-1 receptor agonists were evaluated against placebo in adults without diabetes.

Sources[3]pubmedRole of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.A frequentist random-effects NMA of RCTs comparing oral GLP-1 RAs with placebo in adults without diabetes was conducted by searching databases through 30 April 2026.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “A frequentist random-effects NMA of RCTs comparing oral GLP-1 RAs with placebo in adults without diabetes was conducted by searching databases through 30 April 2026.”

    Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials. · METHODS

    pubmed:42564827:5181d1d18719:5181d1d18719

Comparative evidence

Tolerability endpoints included treatment discontinuation attributed to any adverse event and discontinuation attributed specifically to gastrointestinal adverse events.

Sources[1]pubmedOral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.tolerability outcomes (treatment discontinuation due to any adverse event [AE] and due to gastrointestinal [GI] AEs) were analysed.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “tolerability outcomes (treatment discontinuation due to any adverse event [AE] and due to gastrointestinal [GI] AEs) were analysed.”

    Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. · MATERIALS AND METHODS

    pubmed:42225305:44ec8ec6b2a2:44ec8ec6b2a2

Study findings

The ATTAIN-OSA program is intended to assess both efficacy and safety of orally administered orforglipron in adults with moderate-to-severe obstructive sleep apnea.

Sources[2]pubmedOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.ATTAIN-OSA was developed to evaluate the efficacy and safety of oral orforglipron in adults with moderate-to-severe OSA.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “ATTAIN-OSA was developed to evaluate the efficacy and safety of oral orforglipron in adults with moderate-to-severe OSA.”

    Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. · INTRODUCTION

    pubmed:42383207:f6b63476bfbd:f6b63476bfbd

Study findings

Secondary outcome assessment includes sleep apnea-specific hypoxic burden, PROMIS sleep-related impairment, high-sensitivity C-reactive protein, and body weight.

Sources[2]pubmedOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.Key secondary endpoints include sleep apnea-specific hypoxic burden, Patient-Reported Outcomes Measurement Information System sleep-related impairment, high-sensitivity C-reactive protein, and body weight
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Key secondary endpoints include sleep apnea-specific hypoxic burden, Patient-Reported Outcomes Measurement Information System sleep-related impairment, high-sensitivity C-reactive protein, and body weight”

    Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. · RESULTS

    pubmed:42383207:f6b63476bfbd:f6b63476bfbd

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, regulatory, safety
  • 33 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (15), assurance_score_below_0.72 (12), current_regulatory_source_required (4), extraction_ambiguity (29), high_risk_requires_regulatory_or_two_independent_sources (16), no_direct_support (27)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-21T17:41:39Z

  2. Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-20T08:28:52Z

  3. Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-18T20:56:12Z

  4. Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-22T08:27:44Z

Publication history and provenance

Version 4 · Automated assessment · 2026-08-28T12:09:49Z

084982fa127ca064cb41e4ba62b4c219982a83dd9a7c36846eddfb338e433aff